SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.16-3.2%Dec 1 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (16452)11/22/2003 1:49:17 AM
From: Bluegreen  Read Replies (1) of 17367
 
I TOLD YOU SO!!!!!!!!!!!!!!!! I TOLD YOU SO!!!!!!!!!!!!!!!! Read the very last sentence about the REAL DEBATE!!!!!!!!!!!!!!!!!!!! IT IS ALREADY STARTING just like I said. How in the world can you deny these biologics in this category of Psoriasis? DEGREE of Psoriasis is determined by WHO?????? Who really is in the gray zone of maybe moderate or maybe not???? What about patients that have flares into at least moderate?????? THE DEBATE HAS JUST BEGUN. Folks this could be a HUGE market!!! Funny how analysts have NO clue. Remember when Enbrel was SUPPOSED to be reserved for ONLY certain patients having Rheumatoid arthritis........hence the big shortage of Enbrel not long ago???? Where were the analysts on that?????? Yes indeed the DEATE has just BEGUN!!!!!!!!!!!!!!!!!!!!!!!!!!!! Again read the last part>>>>>>>>>http://www.lifeclinic.com/healthnews/article_view.asp?story=516122
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext